EP-1043(EP-1043) - _专利_临床

概要

基本信息

药物类型

预防性疫苗、重组亚单位疫苗

别名

Recombinant protein vaccine EP-1043

靶点-

作用机制

免疫刺激剂

治疗领域

免疫系统疾病感染泌尿生殖系统疾病

在研适应症-

非在研适应症

HIV感染

原研机构

Onyvax Ltd.

在研机构-

非在研机构

Onyvax Ltd.Pharmexa-Epimmune, Inc.National Institute of Allergy & Infectious Diseases

最高研发阶段无进展临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

1

项与 EP-1043 相关的临床试验

NCT00141024 / Completed临床1期IIT

A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of the Recombinant Protein Vaccine EP-1043 and the DNA Vaccine EP HIV-1090 Given Alone or in Combination in Healthy, HIV-1-Uninfected Adult Participants

The purpose of the study is to determine the safety of and immune response to the investigational HIV vaccine, EP HIV-1090, in HIV uninfected adults.

开始日期2006-01-01

申办/合作机构

National Institute of Allergy & Infectious Diseases

100 项与 EP-1043 相关的临床结果

登录后查看更多信息

100 项与 EP-1043 相关的转化医学

登录后查看更多信息

100 项与 EP-1043 相关的专利（医药）

登录后查看更多信息

1

项与 EP-1043 相关的文献（医药）

2009-11-01·Vaccine3区 · 医学

A novel HIV T helper epitope-based vaccine elicits cytokine-secreting HIV-specific CD4+ T cells in a Phase I clinical trial in HIV-uninfected adults

3区 · 医学

Article

作者: Michael Keefer ; Stephen De-Rosa ; Xia Jin ; Jonathan Fuchs ; Brian D Livingston ; Denise M McKinney ; Mark J Newman ; Margaret Wecker ; Olivier D Defawe ; Elizabeth Noonan ; Evan Thomas ; Cristine Cooper ; William Blattner ; Allan Decamp

A Phase I human vaccine trial of a novel polypeptide vaccine of HIV T helper epitopes (EP-1043) and a DNA vaccine of HIV CTL epitopes was conducted in 84 healthy adult volunteers. The vaccine immunogenicity was assessed by an intracellular cytokine staining assay for IL-2, IL-4, TNF-alpha and IFN-gamma. Sixty eight percent (32/47) of subjects had a positive CD4+ T response after receiving two vaccinations of the polypeptide vaccine. The responding CD4+ T cells made various combinations of IL-2, IL-4, IFN-gamma, and TNF-alpha. The study demonstrated that the EP-1043 vaccine is safe, well-tolerated, and immunogenic.

100 项与 EP-1043 相关的药物交易

登录后查看更多信息